RhumbLine Advisers’s iRadimed IRMD Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q1
$1.3M Sell
13,503
-89
-0.7% -$8.9K ﹤0.01% 2067
2025
Q4
$1.32M Buy
13,592
+631
+5% +$54.1K ﹤0.01% 2079
2025
Q3
$922K Sell
12,961
-6,580
-34% -$438K ﹤0.01% 2296
2025
Q2
$1.17M Buy
19,541
+5,838
+43% +$320K ﹤0.01% 2166
2025
Q1
$719K Sell
13,703
-5,549
-29% -$312K ﹤0.01% 2337
2024
Q4
$1.06M Buy
19,252
+6,062
+46% +$319K ﹤0.01% 2226
2024
Q3
$663K Buy
13,190
+2,221
+20% +$102K ﹤0.01% 2516
2024
Q2
$482K Buy
10,969
+1,132
+12% +$48.1K ﹤0.01% 2702
2024
Q1
$433K Buy
9,837
+319
+3% +$14.1K ﹤0.01% 2754
2023
Q4
$452K Sell
9,518
-87
-0.9% -$3.66K ﹤0.01% 2724
2023
Q3
$426K Buy
9,605
+385
+4% +$17.9K ﹤0.01% 2702
2023
Q2
$440K Sell
9,220
-135
-1% -$6.09K ﹤0.01% 2776
2023
Q1
$368K Buy
9,355
+204
+2% +$7.41K ﹤0.01% 2547
2022
Q4
$259K Buy
9,151
+290
+3% +$8.3K ﹤0.01% 2722
2022
Q3
$266K Buy
8,861
+572
+7% +$19.9K ﹤0.01% 2778
2022
Q2
$281K Buy
8,289
+2,364
+40% +$84.7K ﹤0.01% 2791
2022
Q1
$266K Buy
5,925
+747
+14% +$34.5K ﹤0.01% 2678
2021
Q4
$239K Buy
+5,178
New +$209K ﹤0.01% 2784

Other funds holding IRMD

RhumbLine Advisers's IRMD Position: Q1 2026 in Review

RhumbLine Advisers reduced its iRadimed (IRMD) stake by 0.65% in Q1 2026, selling an estimated $8.9K and leaving 13,503 shares worth $1.3M. The position accounts for ﹤0.01% of the portfolio, ranked #2067.

RhumbLine Advisers first reported a position in IRMD in Q4 2021 and has held it in 18 quarters since. The position peaked at $1.32M in Q4 2025. 228 funds tracked by Wall St. Rank hold IRMD as of Q1 2026.

  • RhumbLine Advisers held 13,503 shares of iRadimed worth $1.3M as of Q1 2026.
  • RhumbLine Advisers sold 89 iRadimed shares in Q1 2026, an estimated $8.9K.
  • iRadimed made up ﹤0.01% of RhumbLine Advisers's portfolio in Q1 2026, its #2067 holding.
  • RhumbLine Advisers first reported a position in iRadimed in Q4 2021 and has held it in 18 quarters since.
  • RhumbLine Advisers's iRadimed position peaked at $1.32M in Q4 2025.
  • 228 funds tracked by Wall St. Rank held iRadimed as of Q1 2026.

Based on RhumbLine Advisers's 13F filing for Q1 2026, filed 12 May 2026.